Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
209,618,986
-
Total 13F shares
-
174,329,025
-
Share change
-
-4,443,130
-
Total reported value
-
$1,077,168,420
-
Put/Call ratio
-
112%
-
Price per share
-
$6.18
-
Number of holders
-
238
-
Value change
-
-$19,756,856
-
Number of buys
-
123
-
Number of sells
-
104
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q2 2024
As of 30 Jun 2024,
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) was held by
238 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
174,329,025 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, Avoro Capital Advisors LLC, STATE STREET CORP, Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ALKEON CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Caligan Partners LP, and Nuveen Asset Management, LLC.
This page lists
238
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.